SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?

Dario Pitocco, Alfredo Pontecorvi, Salvatore Caputo, Linda Tartaglione, Luca Viti, Mauro Di Leo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

12 Citazioni (Scopus)

Abstract

Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but (1) lack of demonstration of SARS-CoV2 binding to DPP4 (2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV) (3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and (4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn't represent a plausible approach to mitigate COVID-19.
Lingua originaleEnglish
pagine (da-a)163-166
Numero di pagine4
RivistaDiabetes Research and Clinical Practice
Volume2020
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • DPP4 inhibition
  • SARS-CoV-2
  • type 1 diabetes mellitus

Fingerprint Entra nei temi di ricerca di 'SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?'. Insieme formano una fingerprint unica.

Cita questo